JD Durkin: Prahlad Singh is president and CEO of Revvity, not just an incredible guest to talk to on this Friday, but a guest who just rang the closing bell. Nice to see you here today.
Prahlad Singh: Same here, JD. Thank you.
JD Durkin: You make tools in tech to help scientists develop new drugs and improve health care. Talk to me about not just the experience of ringing the closing bell today, but the last time you and the team at Revvity were here, back in 2023.
Prahlad Singh: You know, it’s a surreal experience. Three years ago, when we launched Revvity in May of ‘23, that was the opening bell. And to be able to do this today, it sort of brings it back full circle. So it’s really a very good experience for us and the team, three years later.
JD Durkin: Talk to me first and foremost about some of the ways that your fundamental business has continued to evolve, and who’s lucky enough to count themselves among your customers today.
Prahlad Singh: Well, you know, every newborn in the US is tested by us at birth. So we screen 40 million newborns annually, and every newborn in the US is tested by us. So it is not just a business for us, it’s also a purpose. We save 75 plus newborns every day by the testing that we do. And especially now, with pharma and biotech taking a turn, we are at the forefront of drug discovery and development, and we are a partner to all our customers in that domain too.
JD Durkin: And I’d have to imagine in these last few years, the proliferation of artificial intelligence has continued to evolve the worlds of drug discovery, diagnostics and everything in between. What is actually changing for scientists on the front line, and how is Revvity helping with that ongoing transformation?
Prahlad Singh: Actually, that was a core part of our discussion today at Investor Day. Our Signals software platform business is really at the forefront. [unclear: “We are in every research scientist.”] There are more than a million users of our Signals software platform, and AI has really augmented the use of that. And in the history of that business, 2026 is a year where we have some of the most key and critical launches that will make the business very successful as we look into the future.
JD Durkin: So to your point about Investor Day today, let’s drill down a little bit more on Signals software. What makes software, as that unique part of the business, such an important part of not just Revvity’s work today, but where you see the business going from here?
Prahlad Singh: I mean, every clinical researcher, as they do their drug discovery, when they turn their laptop on, they start their work on the Signals platform. So essentially we are core and at the center of drug discovery today. And if you add on to that our ability to provide differentiated reagents and instruments, we sort of complete the full circle in preclinical drug discovery, as a lead candidate comes from early discovery on to development. We are the partner of choice for pharma and biotech today.
JD Durkin: If I ask you a little bit about the quarter, you beat expectations for Q3. Maybe even more importantly, you lifted your full-year guidance. Congratulations on both those points. As you look at the year ahead, could be Q4, could be 2027 and beyond, where do you still see the biggest untapped opportunities for growth?
Prahlad Singh: I mean, needless to say, AI is one aspect we’ve talked about. We gave some consideration for guidance into 2027 and a long-range plan, and assuming the market grows 4 to 6%, we expect to grow at least 200 bps above market. So we’ve got very good traction. As we look into the future, we’ve talked about double-digit EPS growth. So we’ve got all the right elements in place now, especially as we look at the technological revolution that we all are going through.
JD Durkin: And part of that revolution includes some ambitious long-term growth targets. I’ve got less than a minute left. Life sciences, diagnostics, as well as software, which we talked a bit about. What most excites you about where you are on the path for all three of those?
Prahlad Singh: I think, again, being a partner of choice to our customers, being able to bring the differentiated capabilities around reagents and software today. Instruments already has started. We’ve started seeing the impact of drug discovery on our instruments business with AI. I think software and reagents are the ones that are going to be the next leg of growth as we look into the future.
JD Durkin: Prahlad Singh is the president and CEO of Revvity. Congratulations on returning to the New York Stock Exchange, this time for the closing bell. Really grateful for a few minutes of your time. Thanks for chatting with us today.
Prahlad Singh: Thank you very much. Appreciate it. Take care and enjoy your weekend.
